Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial.
K36 Therapeutics does not currently offer expanded access to any of our investigational products.
We understand that for patients with serious diseases such as cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trial programs provides the best path to meet our goal of providing therapeutics to patients with cancer.
We may reevaluate the status of our Expanded Access Policy as development of our investigational products progresses. K36 Therapeutics reserves the right to revise this Expanded Access Policy at any time.
We encourage you to speak with your physician about options that may be right for you.
For any questions regarding access to our investigational therapies, please contact email@example.com, and a member of our team will respond to you within 5 business days.